Ahmedabad (Gujarat) [India], December 20: Intas Pharmaceuticals Ltd., a leading multinational pharmaceutical company, has announced today a strategic exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) for a biosimilar
According to new research, a biomarker signature can predict how well kidney cancer patients will respond to immunotherapy before treatment even starts. This biomarker signature is made up of the number of immune cells in and around kidney tumours, the volume of dead cancer tissue, and mutat
Washington D.C. [USA], Nov. 13 (ANI): A new study has found that tumor necrosis factor (TNF) inhibitors, a group of biologic drugs used to treat children with juvenile idiopathic arthritis, is not linked to a possible increased risk of cancer.